TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02793648

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ascorbic Acid
Description: Two daily oral doses of 200mg of encapsulated vitamin C twice a day, administered at breakfast and dinner

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alpha tocopherol
Description: Two daily oral doses of 200mg of encapsulated vitamin E twice a day, administered at breakfast and dinner

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: PLACEBO
Description: Two daily oral doses of 200mg of encapsulated placebo, administered at breakfast and dinner
Study: NCT00881088

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nadroparin
Description: nadroparin 0,3 cc once daily during immobilization period

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fondaparinux
Description: Fondaparinux 2,5 mg daily during immobilization period
Study: NCT01641380

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Text Messaging Intervention
Description: 1. Online enrollment in the Compliance for Life® (CFL) system through iReminder)~2. Welcome Message 24 hrs after enrollment~3. Appointment Reminder prior to 3 month injection cycles~4. Monthly health reminders i. Condom use ii. Weight control iii. Side Effect Management 5.6-month STD testing reminder~6.Call for missed appointment or no reply to appointment reminder (or other text message)
Study: NCT03123471

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apremilast
Description: Apremilast 30 mg tablets BID from weeks 0 to 32.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo tablets twice daily (BID) for 16 weeks; placebo participants were switched to apremilast 30 mg at week 16.
Study: NCT03862508

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Plyometric exercises
Description: Jump Drop Jump, dropping the subject from a height of 30cm and then make a vertical jump.~Long jumps asking the athletes to take momentum and make a leap forward trying to reach the greatest possible distance.~Jump Countermovement jump unilaterally, alternating the lower extremities. Jumps 180º with the athletes maintaining a semi-squat position. Jump Countermovement jump repeatedly starting from an upright position and the upper extremities in both hips.~All the exercises will be done through 8 repetitions per session during the first two weeks, increasing two repetitions every two weeks (until reaching 12 repetitions at the end of the intervention).~For the realization of each one of the exercises, the ballasted weight will be used (Powerinstep® model).
Study: NCT05367375

Intervention type: PROCEDURE
Intervention: removing osteophyte at patellofemoral joint
Description: to compare anterior knee pain between removing patellofemoral joint osteophytes and non-removing patellofemoral joint osteophytes after medial unicompartmental knee arthroplasty
Study: NCT02977182

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Complete Decongestive Therapy (CDT)
Description: CDT is a multimodal therapy consisting of four components: manual lymph drainage, compression wrapping, exercise, and skin care
Study: NCT01525992

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Community pharmacist-led diabetes education program
Description: A trained pharmacist will counsel each patient based on his/her individual needs about medications, life style and self-care. The pharmacist will use a checklist to document the type of education delivered to each patient. A glucometer is provided for each patient in this arm to monitor blood glucose daily. Three to six visits to the community pharmacy are set during the 6-months study period. At each visit, medication related problems and self-care issues are discussed with the patient and the glucometer test strips are provided for the following month. A telephone call will be made to each patient between visits to ensure adherence to drug therapy and resolve any problems .
Study: NCT02707185

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Simulation-Based Training
Description: An objective assessment tool has been developed and tested in medical code scenarios during training sessions recently done in the simulation lab. The tool has five domains: Airway, Breathing, Circulation, Communications/Leadership, and Defibrillation. Each domain consists of 3-8 tasks and skills.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Simulation-Based Training
Description: An objective assessment tool has been developed and tested in medical code scenarios during training sessions recently done in the simulation lab. The tool has five domains: Airway, Breathing, Circulation, Communications/Leadership, and Defibrillation. Each domain consists of 3-8 tasks and skills.
Study: NCT00834015

Intervention type: OTHER
Group type: OTHER
Intervention: Outcome of lumbar spinal fusion patients and significance of postoperative exercise therapy: A randomized controlled trial
Description: combined strength and aerobic training group
Study: NCT03835091

Intervention type: OTHER
Intervention: BRASS score
Description: Brainstem response on neurologic examination
Study: NCT03123471

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets twice daily (BID) for 16 weeks; placebo participants were switched to apremilast 30 mg at week 16.
Study: NCT01967485

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Text- Messaging
Description: Text messages will be sent to the parents of children enrolled in the study.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual
Description: Children will receive stimulant treatment for ADHD.
Study: NCT04573101

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Music listening / EEG recording
Description: Participants listen to 24 different audio clips of 1 min long each, and select emotion in between. EEG is recorded while participants are listening. Participants select the emotion that best describes their feeling from Table 1 of the PANAS-X. https://www2.psychology.uiowa.edu/faculty/clark/panas-x.pdf

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Music listening / EEG recording
Description: Participants listen to 24 different audio clips of 1 min long each, and select emotion in between. EEG is recorded while participants are listening. Participants select the emotion that best describes their feeling from Table 1 of the PANAS-X. https://www2.psychology.uiowa.edu/faculty/clark/panas-x.pdf
Study: NCT01967485

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treatment as usual
Description: Children will receive stimulant treatment for ADHD.
Study: NCT03661593

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cataract guideline
Description: The patients gets an IOL according to cataract guideline correcting the ametropia
Study: NCT00095212

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 1 Transdermal Testosterone (Patch)
Description: 300 micrograms twice a week

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 2 Placebo Patch
Description: Placebo patch (0 micrograms of testosterone) applied twice a week
Study: NCT04836078

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: open flap subgingival debridement
Description: After the reevaluation phase after that corrective surgical phase started for the three groups. Local infiltration anesthesia administrated then sulcular flaps raised for the purpose of open flap subgingival debridement.Randomization was then performed and concealment from the assessors.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: open flap subgingival debridement
Description: After the reevaluation phase after that corrective surgical phase started for the three groups. Local infiltration anesthesia administrated then sulcular flaps raised for the purpose of open flap subgingival debridement.Randomization was then performed and concealment from the assessors.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: open flap subgingival debridement
Description: After the reevaluation phase after that corrective surgical phase started for the three groups. Local infiltration anesthesia administrated then sulcular flaps raised for the purpose of open flap subgingival debridement.Randomization was then performed and concealment from the assessors.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Subgingival injection of chitosan 2% gel
Description: Group (I); injected subgingivally with chitosan 2% gel containing a microsponges formulated drug weekly

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Subgingival injection of chitosan 2% gel
Description: Group (II); injected subgingivally with chitosan 2% gel containing free drug weekly

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Subgingival injection of chitosan 2% gel
Description: Group (III); injected subgingivally with placebo chitosan 2% gel weekly
Study: NCT04573101

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Music listening / EEG recording
Description: Participants listen to 24 different audio clips of 1 min long each, and select emotion in between. EEG is recorded while participants are listening. Participants select the emotion that best describes their feeling from Table 1 of the PANAS-X. https://www2.psychology.uiowa.edu/faculty/clark/panas-x.pdf

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Music listening / EEG recording
Description: Participants listen to 24 different audio clips of 1 min long each, and select emotion in between. EEG is recorded while participants are listening. Participants select the emotion that best describes their feeling from Table 1 of the PANAS-X. https://www2.psychology.uiowa.edu/faculty/clark/panas-x.pdf

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Music listening / EEG recording
Description: Participants listen to 24 different audio clips of 1 min long each, and select emotion in between. EEG is recorded while participants are listening. Participants select the emotion that best describes their feeling from Table 1 of the PANAS-X. https://www2.psychology.uiowa.edu/faculty/clark/panas-x.pdf

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Music listening / EEG recording
Description: Participants listen to 24 different audio clips of 1 min long each, and select emotion in between. EEG is recorded while participants are listening. Participants select the emotion that best describes their feeling from Table 1 of the PANAS-X. https://www2.psychology.uiowa.edu/faculty/clark/panas-x.pdf
Study: NCT01705015

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: direct feedback about exercise
Study: NCT02870920

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tremelimumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Best Supportive Care

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Best Supportive Care
Study: NCT02071875

Intervention type: DEVICE
Intervention: Nautilus NeuroWaveTM recording
Description: Nautilus NeuroWaveTM recording 15 minute recording with Nautilus NeuroWave Neurodiagnostic .
Study: NCT03687736

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: AbobotulinumtoxinA
Description: AbobotulinumtoxinA treatment in the glabellar region at Baseline and Month 6
Study: NCT02841488

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Continuous peripheral sciatic nerve block
Description: Continuous infusion of local anesthetics through perineural sciatic nerve catheter
Study: NCT01525992

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: The baseline and 6-month follow-up visits to the community pharmacy will be required. If the physician prefers more visits to his office during the study period, it will be granted. The glucometer and a training session about diabetes self-care will be provide at the end of study for control group patients.
Study: NCT01715597

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ascorbic acid
Description: ascorbic acid 2g in normal saline 500ml IV start 30min before the operation and infusion for 2 hour

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: normal saline 500ml IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Normal saline
Description: normal saline 500ml IV
Study: NCT00906971

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: diaphragmatic breathing, isometric training of the abdominal muscles and abdominal massage
Description: Exercises will be conducted by one physiotherapist. A one-minute rest period will be observed between each series. Isometric training of the abdominal muscles: This will consist of a contraction of the upper abdomen muscle and diaphragm and the simultaneous relaxation of the lower abdomen. Training will be carried out in two manners: with the patient lying in a left lateral decubitus position with the hip and knee flexed at 90º and sitting. Breathing exercises: With the patient in a seated position, with one hand placed on the abdomen and the other on the thorax, and will be instructed to breath in slowly,. Two series will be completed, with ten repetitions. Abdominal massage: The physiotherapist will perform slow circular clockwise movements, along the line of the colon, with a regular tennis ball, remaining on each point for one minute, beginning with the ascending colon moving in the direction of the sigmoid colon.
Study: NCT05380362

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Venous Angioplasty
Description: venous angiogram to look for lesions or flaps and then plastying vessels open.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Angioplasty
Description: Patients will be brought to the angio suite and will not know if they are having the venous angioplasty or not.
Study: NCT03725423

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib
Description: 250mg, qd once a day, take it half an hour after meal (the time for taking the medicine should be the same as possible), and take it with warm water. 28 days is a drug delivery cycle.
Study: NCT02753088

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BCD-063

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Copaxone-Teva

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT00573729

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pulsed Dye Laser 577 nm
Description: Comparison of 577 nm Versus 595 nm Wavelengths of Pulsed Dye Laser Treatment of Port Wine Stain Birthmarks

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pulsed Dye Laser 595 nm
Description: Comparison of 577 nm Versus 595 nm Wavelengths of Pulsed Dye Laser Treatment of Port Wine Stain Birthmarks
Study: NCT03468569

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Functional Movement Screen

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Functional Movement Screen

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Functional Movement Screen

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Functional Movement Screen
Study: NCT00633542

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: thalidomide
Description: 100 mg/day orally until progression or severe toxicity

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: interferon alpha
Description: 3 MU 3 times a week until progression or severe toxicity
Study: NCT00830778

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pancreaticojejunostomy
Description: Pancreaticojejunostomy (PJ) reconstruction/anastomosis

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pancreaticogastrostomy
Description: Pancreaticogastrostomy (PG) reconstruction/anastomosis
Study: NCT04972643

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: EPA
Description: EPA 2000mg Soft capsules

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: EPA
Description: EPA 2000mg Soft capsules

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: DHA
Description: DHA 2000mg Soft capsules

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: DHA
Description: DHA 2000mg Soft capsules

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo Soft capsules
Study: NCT02884700

Intervention type: BIOLOGICAL
Intervention: Real-time PCR testing of lower respiratory tract samples
Description: qPCR and high-throughput DNA sequencing testing of lower respiratory tract samples collected routinely in patients with severe legionellosis
Study: NCT00635076

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Patients continued taking the matching placebo that they were taking when they completed Study A6131002 (oral tablets taken once daily).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: alprazolam XR
Description: Patients continued taking the same dosage of alprazolam that they were taking when they completed Study A6131002 (oral tablets taken once daily (1-6mg)); patients taking less than 6 mg/day who failed to show a satisfactory clinical response since the previous visit, and who were free of dose-limiting adverse events, could have their dosage titrated upward by 1 mg/day; upward daily dosage titration of 1 mg was allowed every 7 days, up to a maximum daily dosage of 6 mg/day; patients who were unable to tolerate the previous dosage level of alprazolam XR could have their daily dosage reduced.
Study: NCT01997112

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paracetamol

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Study: NCT02201342

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Udenafil
Description: Drug
Study: NCT01705015

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: PLacebo
Description: UCFit plus encouraged exercise
Study: NCT02700451

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketorolac
Description: Age 18-64: Intravenous Ketorolac 30 milligrams (mg) every 6 hours for 48 hours in addition to patient-controlled analgesia and oral opioids as needed.~Age 65-75: Intravenous Ketorolac 15 milligrams (mg) every 6 hours for 48 hours in addition to patient-controlled analgesia and oral opioids as needed.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Description: Intravenous Acetaminophen 1000mg every 6 hours for 48 hours in addition to patient-controlled analgesia and oral opioids as needed.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intravenous Normal Saline every 6 hours for 48 hours in addition to patient-controlled analgesia and oral opioids as needed.
Study: NCT00454207

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sildenafil citrate (UK-92,480)
Description: sildenafil citrate (UK-92,480)
Study: NCT02553135

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Injection of AAV2-REP1 (10e11 vg)
Description: Single Group: single arm study
Study: NCT02210663

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: veliparib (ABT-888)
Description: Subjects will be given veliparib twice daily on Days 1-28 every 28 days orally.
Study: NCT01578902

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic ablative body radiotherapy
Description: 35Gy/5 fractions/29 days
Study: NCT01658267

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: nutritional supplement
Description: 2 servings per day
Study: NCT03247621

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Whatsapp

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Article

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: No Phone
Study: NCT02841488

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Description: Use of patient controlled analgesia device with intravenous fentanyl

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine
Study: NCT00151892

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPD476
Description: 2.4 g/day Once Daily (QD)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Asacol
Description: 1.6g/day administered 800 mg Twice Daily (BID)
Study: NCT00708370

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: COACH
Description: COACH Nurse will provide health tele-counselling to patients randomized to COACH arm fortnightly for 24 weeks.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: No intervention for placebo
Description: There will be no COACH health tele-counselling to patients randomized to Standard Care arm.
Study: NCT03883074

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: hyaluronic acid with chondroitin + sulphate + magnesium trisilicate
Description: Melt in mouth tablets (1100 mg)

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: tablets with the same aspect of the active device
Study: NCT01889602

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lorazepam
Description: Lorazepam: 2mg, po, 1x

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lorazepam
Description: Lorazepam: 2mg, po, 1x

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lorazepam
Description: Lorazepam: 2mg, po, 1x

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Non-active placebo, po, 1x

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Non-active placebo, po, 1x

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Non-active placebo, po, 1x

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topiramate 100mg
Description: Topiramate: 100 mg, po, 1x

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topiramate 150mg
Description: Topiramate: 150 mg, po, 1x

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topiramate 200mg
Description: Topiramate: 200 mg, po, 1x
Study: NCT00652184

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ARYS-01 (sorivudine) cream 3% or placebo cream
Description: sorivudine cream 3% or placebo cream twice daily for 10 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARYS-01 (sorivudine) cream 3% or placebo cream
Description: sorivudine cream 3% or placebo cream twice daily for 10 days

Intervention type: DRUG
Group type: OTHER
Intervention: ARYS-01 (sorivudine) cream 3% or placebo cream
Description: sorivudine cream 3% or placebo cream twice daily for 10 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo cream and placebo valaciclovir

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo
Description: placebo cream and placebo valaciclovir

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: placebo cream and placebo valaciclovir

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: valaciclovir
Description: active valaciclovir

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: valaciclovir
Description: active valaciclovir

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: valaciclovir
Description: active valaciclovir

Intervention type: DRUG
Group type: OTHER
Intervention: valaciclovir
Description: active valaciclovir